
    
      The study comprises of:

        -  A Screening Period of maximum 28 days;

        -  Five treatment periods during which subjects will be resident from the morning of Day -2
           until at least 72 hours after dosing in Treatment Period 5; discharged on the morning of
           Day 4 of Treatment Period 5; and

        -  A Follow-up Visit 7 to 14 days after the last dosing.

      Each subject will receive 5 single dose treatments of verinurad and allopurinol or verinurad
      alone and subject will be involved in the study for 52 to 59 days.
    
  